In joint research with the Faculty of Pharmaceutical Sciences, Keio University, we were able to confirm that our liquid terahertz spectroscopy technology is effective in determining cancer risk, so we jointly applied for a patent in January 2023.
In joint research with the Faculty of Pharmaceutical Sciences, Keio University, we were able to confirm that our liquid terahertz spectroscopy technology is effective in determining cancer risk, so we jointly applied for a patent in January 2023.
